In September, QIMR Berghofer welcomed Professor Brandon Wainwright AM as its new Director and CEO. Since commencing the role on 7 September 2026, the internationally recognised scientist has begun leading the Institute into its next chapter, bringing with him decades of experience in medical research and a strong commitment to improving health through scientific discovery.
Professor Wainwright joins QIMR Berghofer with an outstanding track record in medical research, innovation and leadership. He is widely recognised for his groundbreaking contributions to genetics and cancer research, particularly in children’s brain cancer, the number one cause of cancer deaths in children. His pioneering work on a key signalling pathway in brain tumours has led to new treatment options, including a world-first Phase I/II clinical trial called PaedNeoVax, which will test personalised mRNA vaccines for children with aggressive and treatment-resistant brain cancer. The trial, being rolled out across eight hospitals in five Australian states this year, is in collaboration with the South Australian Health and Medical Research Institute (SAHMRI), the University of Queensland (UQ) and the Waddell lab at QIMR Berghofer.
Professor Brandon Wainwright
"What attracted me most to the Institute is its unwavering commitment to changing lives through research.”
Before joining the Institute, Professor Wainwright held several senior leadership positions at UQ, including Director of the Institute for Molecular Bioscience and Co-Director of the Children’s Brain Cancer Centre.
For Professor Wainwright, what makes QIMR Berghofer truly special is its people and its purpose.
"QIMR Berghofer has a remarkable history and reputation for research that improves human health. What attracted me most to the Institute is its unwavering commitment to changing lives through research,” Professor Wainwright said.
"Medical research has the power to transform lives, and I believe some of the most exciting advances are still to come. By fostering collaboration, supporting innovation and investing in great people, we can continue to make a meaningful difference for patients, families and communities."
A key priority for Professor Wainwright is connecting with the many donors and supporters whose generosity helps power research at QIMR Berghofer.
"Every breakthrough is made possible by people who believe in a better future. I am looking forward to meeting many of our donors and supporters, learning what inspires their support, and personally thanking them for the extraordinary contribution they make," Professor Wainwright said.
"Together, we are helping drive discoveries that extend far beyond our laboratories, and I look forward to partnering with our donor community as we shape the future of health and medical research."